Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jierong,Chen

第一单位： State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

作者： Jierong,Chen ^[1] ; Lianghe,Lu ^[2] ; Chunhua,Qu ^[1] ; Gari,A ^[3] ; Fangqi,Deng ^[1] ; Muyan,Cai ^[2] ; Wei,Chen ^[1] ; Lie,Zheng ^[2] ; Jiewei,Chen ^[1]

作者单位： State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. ^[1] Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China. ^[2] Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. ^[3] Department of Pancreatobiliary Surgery, Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. ^[4] Department of Imaging, Sun Yat-sen University Cancer Center, Guangzhou, China. ^[5]

关键词 anti-PD-1 antibody body mass index hepatocellular carcinoma immune-related adverse events progression-free survival

DOI 10.3389/fmed.2022.981001

PMID 36203764

发布时间 2022-10-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in medicine

2022年9卷

981001页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy.

Frontiers in medicine

相似文献

Frontiers in medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy.

Frontiers in medicine

相似文献

Frontiers in medicine

相关期刊

检索历史清除